R1R2R3R4R5R6R7R8R9R10R11R12R13ABD AND E HAVE THE MEANINGS INDICATED IN THE CLAIMS. THE COMPOUNDS OF THE FORMULA I ARE VALUABLE PHARMACOLOGICALLY ACTIVE COMPOUNDS. THEY EXHIBIT A STRONG ANTI-AGGREGATING EFFECT ON PLATELETS AND THUS AN ANTI-THROMBOTIC EFFECT AND ARE SUITABLE E.G. FOR THE THERAPHY AND PROPHYLAXIS OF CARDIO-VASCULAR DISORDERS LIKE THROMBOEMBOLIC DISEASES OR RESTENOSES. THEY ARE REVERSIBLE ANTAGONISTS OF THE PLATELET ADP RECEPTOR P2Y12, AND CAN IN GENERAL BE APPLIED IN CONDITIONS IN WHICH AN UNDESIRED ACTIVATION OF THE PLATELET ADP RECEPTOR P2Y12 IS PRESENT OR FOR THE CURE OR PREVENTION OF WHICH AN INHIBITION OF THE PLATELET ADP RECEPTOR P2Y12 IS INTENDEN. THE INVENTION FURTHERMORE RELATES TO PROCESSES FOR THE PREPARATION OF COMPOUNDS OF THE FORMULA 1, THEIR USE, IN PARTICULAR AS ACTIVE INGREDIENTS IN PHARMACEUTICALS, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM.
